With 0.75 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.38 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $277.89 whereas the lowest price it dropped to was $266.23. The 52-week range on PEN shows that it touched its highest point at $277.34 and its lowest point at $148.00 during that stretch. It currently has a 1-year price target of $264.35. Beta for the stock currently stands at 0.54.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PEN was up-trending over the past week, with a rise of 9.08%, but this was up by 15.46% over a month. Three-month performance surged to 32.20% while six-month performance rose 43.48%. The stock gained 10.20% in the past year, while it has gained 16.15% so far this year. A look at the trailing 12-month EPS for PEN yields 0.86 with Next year EPS estimates of 3.80. For the next quarter, that number is 0.90. This implies an EPS growth rate of 33.66% for this year and 36.12% for next year. EPS is expected to grow by 27.68% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 66.20%.
Float and Shares Shorts:
At present, 38.36 million PEN shares are outstanding with a float of 37.06 million shares on hand for trading. On 2024-12-31, short shares totaled 1.84 million, which was 479.0 higher than short shares on 1732838400. In addition to Mr. Adam Elsesser J.D. as the firm’s Co-Founder, Chairman, President & CEO, Dr. Arani Bose M.D. serves as its Co-Founder & Director.
Institutional Ownership:
Through their ownership of 0.93527 of PEN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, PEN reported revenue of $301039000.0 and operating income of $35364000.0. The EBITDA in the recently reported quarter was $44262000.0 and diluted EPS was $0.75.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PEN since 11 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 5 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PEN analysts setting a high price target of 323.0 and a low target of 230.0, the average target price over the next 12 months is 265.5625. Based on these targets, PEN could surge 17.1% to reach the target high and fall by -16.62% to reach the target low. Reaching the average price target will result in a decline of -3.73% from current levels.
Analysts have provided yearly estimates in a range of $2.97306 being high and $2.6847 being low. For PEN, this leads to a yearly average estimate of $2.79408. Based on analyst estimates, the high estimate for the next quarter is $1.05 and the low estimate is $0.63. The average estimate for the next quarter is thus $0.75.
